Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&offset=1860&ordering=-end_effective
{ "count": 2264, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=1880&ordering=-end_effective", "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=1840&ordering=-end_effective", "results": [ { "id": 2520, "title": { "de": "CORA-BGF 2011 Untersuchung der positiven Auswirkungen erhöhter Gravitationsbelastung auf die Kreislaufbelastbarkeit", "en": "CORA-BGF 2011 Untersuchung der positiven Auswirkungen erhöhter Gravitationsbelastung auf die Kreislaufbelastbarkeit" }, "short": "CORA GBF", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-07-01T02:00:00+02:00", "begin_effective": "2011-07-01T02:00:00+02:00", "end_planned": "2012-03-30T02:00:00+02:00", "end_effective": "2012-03-30T02:00:00+02:00", "assignment": "2011-07-05T14:52:27+02:00", "program": null, "subprogram": null, "organization": 14010, "category": 10, "type": 10, "partner_function": 4, "manager": 57932, "contact": 57932, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2520-57932-10" ] }, { "id": 1991, "title": { "de": "Proteomic characterization of mitochondrial ion channels", "en": "Proteomic characterization of mitochondrial ion channels" }, "short": "mitochondrial ion channels", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-01-01T01:00:00+01:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2012-03-13T01:00:00+01:00", "end_effective": "2012-03-13T01:00:00+01:00", "assignment": "2009-11-25T16:00:48+01:00", "program": 69, "subprogram": null, "organization": 14013, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "J2968-B19", "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2495, "title": { "de": "Bipolar affektive Erkrankung und Schwangerschaft, Geburt und Postpartum", "en": "Bipolar affektive Erkrankung und Schwangerschaft, Geburt und Postpartum" }, "short": "Bipolar affektive Erkrankungen", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-05-01T02:00:00+02:00", "begin_effective": "2011-06-01T02:00:00+02:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-06-10T12:18:59+02:00", "program": null, "subprogram": null, "organization": 29444, "category": 10, "type": 10, "partner_function": 4, "manager": 50654, "contact": 50654, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2495-50654-10" ] }, { "id": 1819, "title": { "de": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo", "en": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo" }, "short": "Nano-Health: 4D Imaging of Stem Cells", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T11:50:29+02:00", "program": null, "subprogram": "Nano-Health", "organization": 14082, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1819-50747-12" ] }, { "id": 1716, "title": { "de": "Nano-Health: Nano-structured materials for drug targeting, release and imaging", "en": "Nano-Health: Nano-structured materials for drug targeting, release and imaging" }, "short": "NANO-HEALTH", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-01-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-01-14T14:15:30+01:00", "program": null, "subprogram": "Nano-Initiative", "organization": 28392, "category": 10, "type": 10, "partner_function": 2, "manager": 54033, "contact": null, "status": 2, "research": 5, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1716-54033-10" ] }, { "id": 1732, "title": { "de": "Zerebrale und peripher-muskuläre Gewebssättigung unmittelbar nach der Geburt [Postpartale zerebrale und periphere Oxygenierung bei reifen Neugeborenen und Frühgeborenen]", "en": "Transition after birth: cerebral and peripheral muscle oxygenation in term and preterm neonates" }, "short": "Oxygenierung", "url": null, "abstract": { "de": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring.", "en": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring." }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2009-04-01T02:00:00+02:00", "end_planned": "2011-03-31T02:00:00+02:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-01-19T12:54:11+01:00", "program": 79, "subprogram": null, "organization": 14094, "category": 10, "type": 10, "partner_function": 4, "manager": 50907, "contact": 50907, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1732-50907-10" ] }, { "id": 1820, "title": { "de": "NANO-AS: Nano-Tox-Verlängerung", "en": "NANO-AS: Nano-Tox-Verlängerung" }, "short": "NANO-AS", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T12:36:34+02:00", "program": null, "subprogram": "Nano-Health", "organization": 28394, "category": 10, "type": 10, "partner_function": 2, "manager": 53900, "contact": 53900, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1820-53900-10" ] }, { "id": 1821, "title": { "de": "Nano-Health: Nano-Plaque-Extension", "en": "Nano-Health: Nano-Plaque-Extension" }, "short": "Nano-Plaque-Extension", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-01-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T13:05:25+02:00", "program": null, "subprogram": "Nano-Health Verlängerung", "organization": 14028, "category": 10, "type": 10, "partner_function": 2, "manager": 52854, "contact": 52854, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1821-52854-10" ] }, { "id": 2529, "title": { "de": "Untersuchung der MMP Expression in der humanen Chordomzellinie MUG-Chor 1", "en": "MMP Expression Analysis on the Human Chordoma Cell Line MUG-Chor 1" }, "short": "MMP EXPRESSION ANALYSIS_CHORDOMA CELL", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-06-01T02:00:00+02:00", "begin_effective": "2011-07-01T02:00:00+02:00", "end_planned": "2011-10-01T02:00:00+02:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-07-14T11:48:32+02:00", "program": null, "subprogram": null, "organization": 14052, "category": 10, "type": 10, "partner_function": 4, "manager": 50696, "contact": 50696, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2529-50696-10" ] }, { "id": 2496, "title": { "de": "Einfluss mechanischer Belastung auf die Expression von Matrix Metalloproteasen in Knorpelzellen aus der kindlichen Wachstumsfuge", "en": "Influence of mechanical strain on the expression of Matrix Metalloproteases in chondrocytes from the infant growth plate" }, "short": "KINDLICHE WACHSTUMSFUGE", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-06-01T02:00:00+02:00", "begin_effective": "2011-06-01T02:00:00+02:00", "end_planned": "2011-11-30T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-06-10T12:21:53+02:00", "program": null, "subprogram": null, "organization": 14049, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2414, "title": { "de": "Rolle des enterischen Nervensystems (ENS) auf die Chemotaxis von Leukozyten in der Entzuendung", "en": "Chemoattraction of leukocytes by the enteric nervous system (ENS) during inflammation" }, "short": "CHEMOATTR_LEUKOCYTES_ENS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-11-01T01:00:00+01:00", "begin_effective": "2011-03-01T01:00:00+01:00", "end_planned": "2011-10-31T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2011-02-17T09:32:46+01:00", "program": null, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 4, "manager": 56687, "contact": 56687, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 530 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2414-56687-10" ] }, { "id": 2382, "title": { "de": "INTEROZEPTION KARDIALER AKTIVITÄT, STRESS-REAKTIVITÄT UND ATOPISCHE DERMATITIS", "en": "CARDIAC AWARENESS, STRESS REACTIVITY AND ATOPIC DERMATITIS" }, "short": "CARDIAC AWARE STRESS REACT ATOPIC DERMAT", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-02-01T01:00:00+01:00", "begin_effective": "2011-02-01T01:00:00+01:00", "end_planned": "2012-02-01T01:00:00+01:00", "end_effective": "2012-02-01T01:00:00+01:00", "assignment": "2011-01-19T15:03:26+01:00", "program": null, "subprogram": null, "organization": 29447, "category": 10, "type": 10, "partner_function": 4, "manager": 60040, "contact": 60040, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2382-60040-10" ] }, { "id": 2504, "title": { "de": "Subtyp-spezifische, nicht kompetitive metabotrope Glutamatrezeptor-1 Antoagonisten als neuer alternativer Therapieansatz bei neuroendokrinen Tumoren", "en": "Subtype-specific, non competitive metabotropic glutamatereceptor-1 antagonists as novel alternative therapeutic option for neuroendocrine tumors" }, "short": "glutamate-receptor-1 antagonists", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-07-01T02:00:00+02:00", "begin_effective": "2011-07-01T02:00:00+02:00", "end_planned": "2011-11-30T01:00:00+01:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2011-06-21T11:36:12+02:00", "program": null, "subprogram": null, "organization": 14014, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2365, "title": { "de": "Plasmakonzentration und genetische Polymorphismen von PCSK9 in Patienten mit koronarer Herzkrankheit", "en": "Plasma concentration and polymorphisms of PCSK9 in patients with coronary artery disease " }, "short": "PCSK9", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-01-01T01:00:00+01:00", "begin_effective": "2011-01-01T01:00:00+01:00", "end_planned": "2012-01-31T01:00:00+01:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2010-12-20T12:47:35+01:00", "program": 79, "subprogram": null, "organization": 14028, "category": 10, "type": 10, "partner_function": 4, "manager": 50886, "contact": 50886, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2365-50886-10" ] }, { "id": 2379, "title": { "de": "Die Bedeutung der Th9-Achse bei Psoriasis ", "en": "The role of Th9 in psoriasis" }, "short": "TH9_PSORIASIS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2011-02-01T01:00:00+01:00", "begin_effective": "2011-02-01T01:00:00+01:00", "end_planned": "2012-01-31T01:00:00+01:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2011-01-17T10:12:57+01:00", "program": null, "subprogram": null, "organization": 14047, "category": 10, "type": 10, "partner_function": 4, "manager": 51618, "contact": 51618, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 1161 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2379-51618-10" ] }, { "id": 2418, "title": { "de": "Uveales Melanom: Bio-psycho-soziale Aspekte", "en": "Uveal melanoma: Bio-psyco-social aspects " }, "short": "UVEAL MELANOMA_BIO_PSYCHO_SOCIAL_ASPECTS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-06-01T02:00:00+02:00", "begin_effective": "2011-02-01T01:00:00+01:00", "end_planned": "2011-05-31T02:00:00+02:00", "end_effective": "2012-01-31T01:00:00+01:00", "assignment": "2011-02-17T11:06:13+01:00", "program": null, "subprogram": null, "organization": 14043, "category": 10, "type": 10, "partner_function": 4, "manager": 61522, "contact": 61522, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 938 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2418-61522-10" ] }, { "id": 2092, "title": { "de": "Analysis of germline polymorphisms in the VEGF/VEGFR pathway to predict colorectal cancer outcome", "en": "Analysis of germline polymorphisms in the VEGF/VEGFR pathway to predict colorectal cancer outcome" }, "short": "GERMLINE POLYMORPH VEGF/VEGFR", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-01-01T01:00:00+01:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2010-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2010-02-09T11:47:57+01:00", "program": null, "subprogram": null, "organization": 14085, "category": 10, "type": 10, "partner_function": 4, "manager": 59304, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 894 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2092-59304-10", "2092-58814-12" ] }, { "id": 1329, "title": { "de": "Mapping of the bound proton fraction in the elderly brain", "en": "Mapping of the bound proton fraction in the elderly brain" }, "short": "BOUND_PROTON_ELDERLY_BRAIN_FWF07", "url": null, "abstract": { "de": "The aim of this proposal is to investigate whether the bound pool fraction as a new and quantitative MR measure allows more insight into age related brain tissue changes than other quantitative MR measures. The specific aims are:\r\n\r\n*Develop a MR pulse sequence that allows to map the bound proton fraction on high field systems (>=3T) within a clinically reasonable measurement time (<15min). The sequence should offer whole brain coverage and should overcome current limitations such as the susceptibility for motion and B1 effects.\r\n\r\n*Measure the BPF in brain tissue of a large cohort of the Ausitria Stroke Prevention Study (ASPS). This gives us the opportunity to study a representative and homogeneous group of normal elderly people without a history or signs of neuropsychiatric diseases. By using a younger control cohort, we want to investigate how the BPF changes as a function of age, sex and anatonic region including cortical structures. In addition, we want to find out how the BPF varies within WMH with different severity and how it relates to the BPF in normal appearing brain tissue and to the neurocognitive performance.\r\n\r\n*Compare the sensitivity and specificity of bound proton fraction mapping to more established measures of brain tissue changes including atrophy, diffusion weighted imaging, and magnetization transfer imaging.", "en": "The aim of this proposal is to investigate whether the bound pool fraction as a new and quantitative MR measure allows more insight into age related brain tissue changes than other quantitative MR measures. The specific aims are:\r\n\r\n*Develop a MR pulse sequence that allows to map the bound proton fraction on high field systems (>=3T) within a clinically reasonable measurement time (<15min). The sequence should offer whole brain coverage and should overcome current limitations such as the susceptibility for motion and B1 effects.\r\n\r\n*Measure the BPF in brain tissue of a large cohort of the Ausitria Stroke Prevention Study (ASPS). This gives us the opportunity to study a representative and homogeneous group of normal elderly people without a history or signs of neuropsychiatric diseases. By using a younger control cohort, we want to investigate how the BPF changes as a function of age, sex and anatonic region including cortical structures. In addition, we want to find out how the BPF varies within WMH with different severity and how it relates to the BPF in normal appearing brain tissue and to the neurocognitive performance.\r\n\r\n*Compare the sensitivity and specificity of bound proton fraction mapping to more established measures of brain tissue changes including atrophy, diffusion weighted imaging, and magnetization transfer imaging." }, "begin_planned": "2007-08-01T02:00:00+02:00", "begin_effective": "2008-01-01T01:00:00+01:00", "end_planned": "2010-07-31T02:00:00+02:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2007-07-10T14:42:36+02:00", "program": 72, "subprogram": null, "organization": 14051, "category": 10, "type": 10, "partner_function": 4, "manager": 51279, "contact": 51279, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "P20103", "ethics_committee": null, "edudract_number": null, "persons": [ "1329-51279-10" ] }, { "id": 1771, "title": { "de": "Rett Disorder: The Pre-Regression Period", "en": "Rett Disorder: The Pre-Regression Period" }, "short": "RETT DISORDER", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": null, "begin_effective": "2007-01-01T01:00:00+01:00", "end_planned": null, "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2009-03-30T17:24:34+02:00", "program": null, "subprogram": null, "organization": 14010, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 530 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2031, "title": { "de": "Genetic variants in the RAD51, BRCA1 and BRCA2 genes as predictors of radiation response and toxicity in prostate cancer patients", "en": "Genetic variants in the RAD51, BRCA1 and BRCA2 genes as predictors of radiation response and toxicity in prostate cancer patients" }, "short": "GENETIC_PROSTATE_CANCER_OeNB", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2010-01-01T01:00:00+01:00", "begin_effective": "2010-01-01T01:00:00+01:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2011-12-31T01:00:00+01:00", "assignment": "2010-01-11T15:12:11+01:00", "program": 79, "subprogram": null, "organization": 14060, "category": 10, "type": 10, "partner_function": 4, "manager": 50495, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2031-50495-10", "2031-50910-12" ] } ] }